These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38762799)

  • 1. When the Third Time Is Not the Charm-Trial Outcomes in Idiopathic Pulmonary Fibrosis.
    Zamora AC; Ortega VE; Carmona EM
    JAMA; 2024 Aug; 332(5):374-376. PubMed ID: 38762799
    [No Abstract]   [Full Text] [Related]  

  • 2. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.
    Raghu G; Richeldi L; Fernández Pérez ER; De Salvo MC; Silva RS; Song JW; Ogura T; Xu ZJ; Belloli EA; Zhang X; Seid LL; Poole L;
    JAMA; 2024 Aug; 332(5):380-389. PubMed ID: 38762797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
    Richeldi L; Fernández Pérez ER; Costabel U; Albera C; Lederer DJ; Flaherty KR; Ettinger N; Perez R; Scholand MB; Goldin J; Peony Yu KH; Neff T; Porter S; Zhong M; Gorina E; Kouchakji E; Raghu G
    Lancet Respir Med; 2020 Jan; 8(1):25-33. PubMed ID: 31575509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.
    Hammond M; Clark AB; Cahn AP; Chilvers ER; Fraser WD; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett D; Whyte M; Wilson A
    Trials; 2018 Feb; 19(1):89. PubMed ID: 29402332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough.
    Thabut G; Crestani B; Porcher R; Richeldi L
    Eur Respir J; 2015 Sep; 46(3):607-14. PubMed ID: 26324692
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
    Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW
    Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.
    Raghu G; Scholand MB; de Andrade J; Lancaster L; Mageto Y; Goldin J; Brown KK; Flaherty KR; Wencel M; Wanger J; Neff T; Valone F; Stauffer J; Porter S
    Eur Respir J; 2016 May; 47(5):1481-91. PubMed ID: 26965296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
    Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
    BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Two drugs inhibit disease progression. Idiopathic lung fibrosis treatable for the first time].
    Einecke D
    MMW Fortschr Med; 2015 Feb; 157(2):24-5. PubMed ID: 25743506
    [No Abstract]   [Full Text] [Related]  

  • 11. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.
    Sgalla G; Franciosa C; Simonetti J; Richeldi L
    Expert Opin Investig Drugs; 2020 Aug; 29(8):771-777. PubMed ID: 32447983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
    Maher TM; Kreuter M; Lederer DJ; Brown KK; Wuyts W; Verbruggen N; Stutvoet S; Fieuw A; Ford P; Abi-Saab W; Wijsenbeek M
    BMJ Open Respir Res; 2019; 6(1):e000422. PubMed ID: 31179008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antifibrotic treatment].
    von der Beck D; Löh B; Drakopanagiotakis F; Markart P; Günther A
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2523-5. PubMed ID: 25423462
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.
    Taniguchi H; Kondoh Y; Ebina M; Azuma A; Ogura T; Taguchi Y; Suga M; Takahashi H; Nakata K; Sato A; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Res; 2011 Jul; 12(1):93. PubMed ID: 21756364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone for idiopathic pulmonary fibrosis.
    Bouros D
    Lancet; 2011 May; 377(9779):1727-9. PubMed ID: 21571363
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
    King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
    N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials.
    du Bois RM; Nathan SD; Richeldi L; Schwarz MI; Noble PW
    Am J Respir Crit Care Med; 2012 Oct; 186(8):712-5. PubMed ID: 22798316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon gamma for idiopathic pulmonary fibrosis.
    Bouros D
    Lancet; 2009 Jul; 374(9685):180-2. PubMed ID: 19570574
    [No Abstract]   [Full Text] [Related]  

  • 19. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
    Kreuter M; Wuyts W; Renzoni E; Koschel D; Maher TM; Kolb M; Weycker D; Spagnolo P; Kirchgaessler KU; Herth FJ; Costabel U
    Lancet Respir Med; 2016 May; 4(5):381-9. PubMed ID: 27050871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for disease progression in idiopathic pulmonary fibrosis.
    Raghu G; Ley B; Brown KK; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Noble PW; Song JW; Wells AU; Whelan TP; Lynch DA; Humphries SM; Moreau E; Goodman K; Patterson SD; Smith V; Gong Q; Sundy JS; O'Riordan TG; Martinez FJ
    Thorax; 2020 Jan; 75(1):78-80. PubMed ID: 31611341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.